Cantor Fitzgerald Reaffirms "Overweight" Rating for Ascendis Pharma A/S (NASDAQ:ASND)

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report)'s stock had its "overweight" rating reissued by analysts at Cantor Fitzgerald in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $170.00 price objective on the biotechnology company's stock. Cantor Fitzgerald's target price would suggest a potential upside of 18.07% from the stock's current price.

ASND has been the topic of several other reports. StockNews.com upgraded Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research note on Wednesday, November 20th. Oppenheimer lowered their price target on Ascendis Pharma A/S from $190.00 to $180.00 and set an "outperform" rating on the stock in a research note on Friday, November 15th. Wedbush restated an "outperform" rating and set a $181.00 price target on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. JPMorgan Chase & Co. lifted their price objective on Ascendis Pharma A/S from $165.00 to $167.00 and gave the company an "overweight" rating in a report on Wednesday, January 29th. Finally, UBS Group initiated coverage on Ascendis Pharma A/S in a report on Tuesday, January 7th. They set a "buy" rating and a $196.00 price objective on the stock. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $193.43.

Ascendis Pharma A/S Stock Performance

Shares of Ascendis Pharma A/S stock traded up $1.50 during trading on Tuesday, reaching $143.99. The company's stock had a trading volume of 287,031 shares, compared to its average volume of 484,867. The business's fifty day moving average price is $132.19 and its 200-day moving average price is $132.29. The firm has a market cap of $8.74 billion, a price-to-earnings ratio of -17.78 and a beta of 0.64. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.32) by $0.64. Sell-side analysts anticipate that Ascendis Pharma A/S will post -7.12 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. T. Rowe Price Investment Management Inc. raised its position in Ascendis Pharma A/S by 54.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 2,725,546 shares of the biotechnology company's stock worth $375,226,000 after purchasing an additional 960,504 shares during the last quarter. Capital International Investors raised its position in Ascendis Pharma A/S by 35.7% in the 4th quarter. Capital International Investors now owns 2,863,249 shares of the biotechnology company's stock worth $394,183,000 after purchasing an additional 753,859 shares during the last quarter. Groupama Asset Managment bought a new position in Ascendis Pharma A/S in the 3rd quarter worth approximately $60,000. Janus Henderson Group PLC raised its position in Ascendis Pharma A/S by 6.8% in the 3rd quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company's stock worth $625,075,000 after purchasing an additional 267,881 shares during the last quarter. Finally, Westfield Capital Management Co. LP raised its position in Ascendis Pharma A/S by 3.4% in the 3rd quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company's stock worth $766,523,000 after purchasing an additional 170,942 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.